Effects of statins on serum sCD40, sCD146 and PAPP-An in patients with coronary heart disease
serum sCD40, sCD146 and PAPP-An in patients with coronary heart disease
Abstract
Objective:To analyze the effects of statins on the levels of sCD40, sCD146 and PAPP-An in patients with coronary heart disease (CHD).
Methods:126 patients with CHD treated from September 2022 to September 2024 were divided into study group (n = 84) and control group (n = 42). The study group was randomly divided into group A (n = 42) and group B (n = 42). Patients in the control group were routinely treated with vasodilator, furosemide, digitalis and other cardiotonic agents. On the basis of routine treatment, patients in the study group were treated with Atto vastatin calcium tablets in group An and rosuvastatin calcium tablets in group B. both groups were treated with 20mg/, oral administration before bedtime, and the treatment cycle was 3 months. the cardiac function grade, blood lipid level, serum sCD40, sCD146 and PAPP-A levels and adverse reactions after treatment were compared before and after treatment.
Results:After treatment, the cardiac function of the three groups was improved as compared with that before treatment. The effect of patients in the group A and B was better than control group. The blood lipid levels of the three groups were improved after treatment. The blood lipid level of the group A and B was better than control group. The levels of serum sCD40, sCD146 and PAPP-A between group A and group B were no difference, after treatment, these in group A and B were better than control group. After treatment, there were some adverse reactions in all the three groups.
Conclusion:Statins are effective in the treatment of sCD40, sCD146 and PAPP-An in patients with CHD, can significantly improve the cardiac function and blood lipid levels of patients with CHD, and effectively regulate the levels of sCD40, sCD146 and PAPP-An in patients with coronary heart disease
References
Caterina, R.D., Radico, F. and Marzilli M., 2020. What dictates prognosis in myocardial ischemic syndromes: myocardial ischemia or coronary atherosclerosis? Heart Metab., 81: 23-26. https://doi.org/10.31887/hm.2020.81/rdecaterina
Chen, L., Chen, X.W., Huang, X., Song, B.L., Wang, Y. and Wang, Y., 2019. Regulation of glucose and lipid metabolism in health and disease. Sci. China. Life Sci., 62: 1420-1458. https://doi.org/10.1007/s11427-019-1563-3
Chinetti, G., Fruchart, J.C. and Staels, B., 2003. Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr. Opin. Lipidol., 14: 459-68. https://doi.org/10.1097/00041433-200310000-00006
Danesh, J., 2022. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ, 321: 199-204. https://doi.org/10.1136/bmj.321.7255.199
de Pádua Borges, R., Degobi, N.A.H. and Bertoluci, M.C., 2021. Choosing statins: A review to guide clinical practice. Arch. Endocrinol. Metab., 64: 639-653. https://doi.org/10.20945/2359-3997000000306
Diamantis, E., Kyriakos, G., Quiles-Sanchez, L.V., Farmaki, P. and Troupis, T., 2017. The anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature. Curr. Cardiol. Rev., 13: 209-216. https://doi.org/10.2174/1573403X13666170426104611
Hu, Z.C., Wu, L.M., Liu, S.Y., Shen, L.S., Zhao, M.H., Liu, L.M., Ding, L.G. Zheng, L.H. and Yao, Y., 2019. Clinical characteristics of cardiomyopathies complicated with ventricular thrombosis. Zhonghua Yi Xue Za Zhi, 99: 3587-3591. https://doi.org/10.3760/cma.j.issn.0376-2491.2019.45.011
Huang, S.H., Wu, C.H., Jiang, S., Bahner, I., Lossinsky, A.S. and Jong, A.Y., 2011. HIV-1 gp41 ectodomain enhances cryptococcus neoformans binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities. Biochem. J., 438: 457-66. https://doi.org/10.1042/BJ20110218
Jia, G. and Sowers, J.R., 2021. Hypertension in diabetes: An update of basic mechanisms and clinical disease. Hypertension, 78: 1197-1205. https://doi.org/10.1161/HYPERTENSIONAHA.121.17981
Lopau, K. and Wanner, C., 2021. Treatment rationale for coronary heart disease in advanced CKD. Herz., 46: 221-227. https://doi.org/10.1007/s00059-021-05025-2
Parikh, R.R., Folsom, A.R., Misialek, J.R., Rosamond, W.D., Chang, P.P., Tang W.H. and Cushman, M., 2019. Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure. Thrombo. Res., 182: 89-94. https://doi.org/10.1016/j.thromres.2019.08.009
Sayols-Baixeras, S., Lluís-Ganella, C., Lucas, G. and Elosua, R., 2014. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl. Clin. Genet., 7: 15-32. https://doi.org/10.2147/TACG.S35301
Shami, A., Edsfeldt, A., Bengtsson, E., Nilsson, J., Shore, A.C., Natali, A., Khan, F., Lutgens, E. and Gonçalves, I., 2021. Soluble CD40 levels in plasma are associated with cardiovascular disease and in carotid plaques with a vulnerable phenotype. J. Stroke., 23: 367-376. https://doi.org/10.5853/jos.2021.00178
Wijkman, M.O., Claggett, B., Vaduganathan, M., Cunningham, J.W., Rørth, R., Jackson, A., Packer, M., Zile, M., Rouleau, J., Swedberg, K., Lefkowitz, M., Shah, S.J., Pfeffer, M.A., McMurray, J.J.V. and Solomon, S.D., 2022. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: The PARAGON-HF and PARADIGM-HF trials. Cardiovasc. Diabetol., 21: 110. https://doi.org/10.1186/s12933-022-01545-1
Xue, X., Liu, Y, Yang, M., Wang, S., Huang, M., Gao, S., Xu, Y., Gao, S., Li, L. and Yu, C., 2020. Effect of hypercholesterolemia alone or combined with hypertension on the degree of coronary artery stenosis in patients with coronary heart disease angina pectoris: A medical records based retrospective study protocol. Med. (Baltimore), 99: e22225. https://doi.org/10.1097/MD.0000000000022225
Yang, S.W., Zhou, Y.J., Zhao, Y.X., Liu, Y.Y., Tian, X.F., Wang, Z.J., Jia, D.A., Han, H.Y., Hu, B., Shen, H., Gao, F., Wang, L.Y., Lin, J., Pan, G.Z., Zhang, J., Guo, Z.F., Du, J. and Hu, A.Y., 2017. The serum anion gap is associated with disease severity and all-cause mortality in coronary artery disease. J. Geriatr. Cardiol., 14: 392-400. https://doi.org/10.11909/j.issn.1671-5411.2017.06.008
Zhang, X., Kang, J., Zhang, J., Chen, Y., Dai, H., Hu, M., Liu, Y. and Shang, H., 2023. Effectiveness of Yiqi Fumai lyophilized injection for acute heart failure: Rationale and design of the AUGUST-AHF cohort study. Front. Cardiovasc. Med., 9: 1074406. https://doi.org/10.3389/fcvm.2022.1074406
Copyright (c) 2025 Jing Zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.